MOLNUPIRAVIR-EVA 200 MG 40 CAPS

Molnupiravir is the first oral direct-acting antiviral shown to be highly effective at reducing nasopharyngeal SARS-CoV-2 infectious virus and viral RNA and has a favorable safety and tolerability profile. Molnupiravir is not a substitute for vaccination in individuals for whom COVID-19 vaccination and a booster dose are recommended. Molnupiravir is administered as four 200 milligram capsules taken orally every 12 hours for five days for a total of 40 capsules.